Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use

Article Clinical Neurology

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study

James Howard et al.

NEUROLOGY (2023)

Review Clinical Neurology

Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management

Fiammetta Vanoli et al.

Summary: Myasthenia gravis is a neurological autoimmune disorder characterized by muscle weakness and fatigue. The current treatment mainly relies on non-specific immunosuppression, but monoclonal antibody-based therapies offer a more target-specific approach. Some monoclonal antibodies targeting different immunopathological pathways have been approved for the treatment of MG, while others are under investigation, expanding the therapeutic possibilities for this condition.

NEUROTHERAPEUTICS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals

Deepak Menon et al.

Summary: Myasthenia gravis is an autoimmune disorder that affects the neuromuscular junctions, leading to a wide range of symptoms. Traditional treatment options have weak evidence, while newer biological agents offer more targeted and effective therapy.

DRUGS (2022)

Add to Collection

Article Medicine, General & Internal

Current Treatment of Myasthenia Gravis

Mohammed K. Alhaidar et al.

Summary: This review summarizes the current treatment options for myasthenia gravis (MG), including immunosuppressive and non-immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Meeting Abstract Clinical Neurology

LONG-TERM ASSESSMENT OF EFGARTIGIMOD IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: ADAPT plus STUDY INTERIM RESULTS

Saiju Jacob et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Add to Collection

Review Immunology

Update in immunosuppressive therapy of myasthenia gravis

Agustina M. Lascano et al.

Summary: Myasthenia gravis is an autoimmune disease of the neuromuscular junction, and treatment requires careful consideration to avoid the risks associated with long-term systemic steroid administration. Emerging therapies for MG focus on using biological drugs and targeting new pathways of the immune system to address disease heterogeneity.

AUTOIMMUNITY REVIEWS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis

Rui Chen et al.

Summary: This study analyzed the efficacy characteristics of nine drugs, with eculizumab showing the highest efficacy in reducing QMGs scores and efgartigimod showing the highest efficacy in reducing MG-ADLs scores. Additionally, the study found that daily living activities improved with the increase in patients undergoing thymectomy.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article

Current and Upcoming Treatment Modalities in Myasthenia Gravis

Swathi Beladakere Ramaswamy et al.

Journal of Clinical Neuromuscular Disease (2021)

Add to Collection

Article Clinical Neurology

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Jr Jr Howard et al.

Summary: The study evaluated the safety and efficacy of efgartigimod in patients with generalised myasthenia gravis, showing that it was well tolerated and efficacious. The unique feature of individualized dosing based on clinical response in the study will provide further insights into clinical practice with longer term data from the ongoing open-label extension.

LANCET NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations

Laura Dresser et al.

Summary: Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The core clinical manifestation is fatigable muscle weakness, which may vary according to the type of autoantibody and whether a thymoma is present.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Clinical Neurology